Inhibitory activities of selected Kampo formulations on human aldose reductase

Complex Regulation of PKCβ2 and PDK-1/AKT by ROCK2 in Diabetic Heart

(2014) Guorong Lin et al.   PLoS One

Mechanisms of Diabetic Complications

(2013) Josephine M. Forbes et al.   PHYSIOLOGICAL REVIEWS

Aldose reductase inhibitors zopolrestat and ferulic acid alleviate hypertension associated with diabetes: effect on vascular reactivity

(2012) Dina Badawy et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly

(2012) Hiroyuki Umegaki et al.   Geriatrics & Gerontology International

Isoliquiritigenin is a Novel NMDA Receptor Antagonist in Kampo Medicine Yokukansan

(2011) Zenji Kawakami et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

(2011) David R. Whiting et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Advanced Glycation end Products, Oxidative Stress and Diabetic Nephropathy

(2010) Sho-ichi Yamagishi et al.   Oxidative Medicine and Cellular Longevity

Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat

(2008) N Hotta et al.   DIABETIC MEDICINE

Inhibitory activities of prenylated flavonoids fromSophora flavescensagainst aldose reductase and generation of advanced glycation endproducts

(2008) Hyun Ah Jung et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications

(2007) Giuseppina Basta   ATHEROSCLEROSIS